Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
229 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00005091 | DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | completed | Phase 2 | — | Daiichi PharmaceuticalsINDUSTRY | 5 | Jul 10, 2013 | clinicaltrials |
| NCT00530764 | A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.(SPRAY) | completed | Phase 2 | 360 | GW Pharmaceuticals LtdINDUSTRY | 16 | Jun 20, 2013 | clinicaltrials |
| NCT00114790 | Boronophenylalanine (BPA)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment Head and Neck Tumors | completed | Phase 1 / Phase 2 | 30 | Boneca CorporationINDUSTRY | 1 | May 6, 2013 | clinicaltrials |
| NCT00090363 | ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA) | completed | Phase 2 | 447 | AstraZenecaINDUSTRY | 14 | Jan 8, 2013 | clinicaltrials |
| NCT00558363 | ARTS - AVODART After Radical Therapy For Prostate Cancer Study(ARTS) | completed | Phase 2 | 294 | GlaxoSmithKlineINDUSTRY | 9 | Mar 21, 2012 | clinicaltrials |
| NCT00003304 | Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors | completed | Phase 2 | 29 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Mar 6, 2012 | clinicaltrials |
| NCT00101660 | Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib | completed | Phase 2 | 387 | Bristol-Myers SquibbINDUSTRY | 22 | Mar 2, 2012 | clinicaltrials |
| NCT00501735 | Forodesine in the Treatment of Cutaneous T-Cell Lymphoma | completed | Phase 2 | 144 | BioCryst PharmaceuticalsINDUSTRY | 10 | Jan 23, 2012 | clinicaltrials |
| NCT00791947 | A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT | completed | Phase 2 | 166 | University of AarhusOTHER | 3 | Sep 8, 2011 | clinicaltrials |
| NCT00101647 | Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia | completed | Phase 2 | 197 | Bristol-Myers SquibbINDUSTRY | 23 | Apr 15, 2011 | clinicaltrials |
| NCT00101595 | Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | completed | Phase 2 | 96 | Bristol-Myers SquibbINDUSTRY | 20 | Apr 14, 2011 | clinicaltrials |
| NCT00268892 | Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer | completed | Phase 2 / Phase 3 | 278 | Ferring PharmaceuticalsINDUSTRY | 10 | Dec 24, 2010 | clinicaltrials |
| NCT00116753 | A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer | completed | Phase 2 | 460 | Ferring PharmaceuticalsINDUSTRY | 11 | Dec 10, 2010 | clinicaltrials |
| NCT00101816 | Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate | completed | Phase 2 | 124 | Bristol-Myers SquibbINDUSTRY | 20 | Aug 10, 2010 | clinicaltrials |
| NCT00103844 | Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia | completed | Phase 2 | 150 | Bristol-Myers SquibbINDUSTRY | 32 | Aug 10, 2010 | clinicaltrials |
| NCT00117299 | PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib | completed | Phase 2 | 45 | University of HelsinkiOTHER | 1 | May 27, 2010 | clinicaltrials |
| NCT00174772 | Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 72 | SanofiINDUSTRY | 8 | Feb 17, 2010 | clinicaltrials |
| NCT01062490 | Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS) | completed | Phase 2 | 45 | medac GmbHINDUSTRY | 1 | Feb 4, 2010 | clinicaltrials |
| NCT00237900 | Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer | terminated | Phase 1 / Phase 2 | 34 | AstraZenecaINDUSTRY | 1 | Apr 23, 2009 | clinicaltrials |
| NCT00239291 | Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 42 | AstraZenecaINDUSTRY | 1 | Apr 23, 2009 | clinicaltrials |
| NCT00241475 | Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy | completed | Phase 2 | 30 | AstraZenecaINDUSTRY | 1 | Apr 23, 2009 | clinicaltrials |
| NCT00308607 | Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma | completed | Phase 2 | 27 | University of TurkuOTHER | 1 | Apr 3, 2009 | clinicaltrials |
| NCT00115440 | BNCT to Treat Glioma That Has Progressed Following Radiotherapy | completed | Phase 1 / Phase 2 | 22 | Boneca CorporationINDUSTRY | 1 | Jan 28, 2009 | clinicaltrials |
| NCT00115453 | Boron Neutron Capture Therapy (BNCT) as Treatment of Glioblastoma | terminated | Phase 1 / Phase 2 | 50 | Boneca CorporationINDUSTRY | 1 | Aug 18, 2008 | clinicaltrials |
| NCT00669370 | Biweekly Docetaxel in Combination With Capecitabine as First-Line Treatment in Patients With Advanced Gastric Cancer(GAST-TaxXel) | unknown | Phase 2 | 50 | University of TurkuOTHER | 1 | Apr 30, 2008 | clinicaltrials |
| NCT00239304 | Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer | completed | Phase 1 / Phase 2 | 40 | AstraZenecaINDUSTRY | 1 | Dec 18, 2007 | clinicaltrials |
| NCT00381368 | Safety and Efficacy Study of Intravenous Loading Dose of Ibandronate in Breast Cancer Patients | unknown | Phase 2 | 60 | University of TurkuOTHER | 1 | Dec 4, 2006 | clinicaltrials |
| NCT00034593 | A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | — | Eli Lilly and CompanyINDUSTRY | 3 | Jul 19, 2006 | clinicaltrials |
| NCT00035334 | Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis | completed | Phase 2 / Phase 3 | 150 | Bellus Health Inc. - a GSK companyINDUSTRY | 12 | Feb 14, 2006 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials